Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Oxford BioMedica ( (GB:OXB) ) just unveiled an update.
Oxford Biomedica said all resolutions proposed at its 7 May annual general meeting in Oxford were approved by poll, confirming shareholder support for the company’s governance and strategic direction. Investors backed the adoption of the 2025 annual report and accounts, the directors’ remuneration report and the reappointment of all serving board members.
Shareholders also renewed the mandate to appoint PricewaterhouseCoopers as auditor, authorised the board to allot new shares and approved the disapplication of pre-emption rights for capital raising, acquisitions and investments. The meeting further granted flexibility to call general meetings on 14 days’ notice, enhancing the company’s ability to respond quickly to financing or strategic opportunities in the competitive cell and gene therapy CDMO market.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £1170.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Spark’s Take on OXB Stock
According to Spark, TipRanks’ AI Analyst, OXB is a Neutral.
The score is held back primarily by weak financial performance (still loss-making with negative operating/free cash flow despite improvement) and bearish technicals (price below key moving averages with negative MACD and weak RSI). Valuation provides limited support due to negative earnings and no dividend yield data.
To see Spark’s full report on OXB stock, click here.
More about Oxford BioMedica
Oxford Biomedica (OXB) is a global cell and gene therapy contract development and manufacturing organisation that focuses on viral vector technologies supporting innovative pharmaceutical and biotechnology clients. The FTSE 250 and FTSE4Good-listed group offers end-to-end capabilities from early-stage development to commercialisation, leveraging platforms such as its TetraVecta lentiviral system and AAV production technologies across sites in the UK, France and the U.S.
With 30 years of experience as a pioneer in viral vectors, Oxford Biomedica provides development and manufacturing for lentivirus, AAV, adenovirus and other vector types, underpinned by robust quality, analytical and regulatory frameworks. Its geographically diversified facilities in Oxfordshire, Lyon, Strasbourg, Bedford, Massachusetts and Durham, North Carolina position the company as a key partner in delivering advanced therapies worldwide.
Average Trading Volume: 324,904
Technical Sentiment Signal: Strong Buy
Current Market Cap: £779.9M
For detailed information about OXB stock, go to TipRanks’ Stock Analysis page.